Rutgers, The State University of New Jersey

University of Texas System

Kalyan Das

Gaetano T Montelione

Robert M Krug

Rong Xiao

Edward Arnold

Karen Y Twu

Rei-Lin Kuo

Eddy Arnold

Joseph David Bauman

Edmond Joseph LaVoie

Ajit S Parhi

Disha Patel

Hye Yeon Sagong

Suyambu Kesava Vijayan

Li-Chung Ma

LiChung Ma

John E Kerrigan

Cody Kelley

Dishaben V Patel

The invention provides compounds of formula I: and salts and prodrugs thereof wherein R, Xand Xhave any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones

The invention provides compounds of formula (I) and salts thereof wherein R-Rhave any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties. 

Therapeutic hydroxyquinolones

The invention provides compounds of formula I: and salts thereof wherein R-Rhave any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts, and methods for their use in therapy. The compounds have useful antiviral properties.

Therapeutic catechols

The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties. 

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Influenza A virus vaccines and inhibitors

The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Inhibitors of influenza endonuclease activity and tools for their discovery

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF 30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

Growing community of inventors

East Brunswick, NJ, United States of America

Kalyan Das